Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for China Pharma Holdings (CPHI) over the last 14 years, with Sep 2025 value amounting to -$40,598.

  • China Pharma Holdings' Cash from Investing Activities fell 540.33% to -$40,598 in Q3 2025 from the same period last year, while for Sep 2025 it was -$404,336, marking a year-over-year decrease of 594.01%. This contributed to the annual value of -$291,718 for FY2024, which is 2432.93% down from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Cash from Investing Activities is -$40,598, which was down 309.21% from -$9,921 recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Cash from Investing Activities ranged from a high of $55,964 in Q1 2023 and a low of -$415,977 during Q3 2021.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$9,921 (2025), whereas its average is -$45,181.
  • Per our database at Business Quant, China Pharma Holdings' Cash from Investing Activities skyrocketed by 4,123.29% in 2023 and then slumped by 5,927.21% in 2024.
  • Quarterly analysis of 5 years shows China Pharma Holdings' Cash from Investing Activities stood at -$7,056 in 2021, then skyrocketed by 486.45% to $27,268 in 2022, then slumped by 116.60% to -$4,527 in 2023, then crashed by 5,927.21% to -$272,852 in 2024, then slumped by 540.33% to -$40,598 in 2025.
  • Its last three reported values are -$40,598 in Q3 2025, -$9,921 for Q2 2025, and -$80,965 during Q1 2025.